The MarketWatch News Department was not involved in the creation of this content. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising ...

Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

But the FDA’s decision does not preclude CMS from determining that the higher dose is not reasonable and necessary — ...

Meagan Johnson recently spent four days calling dozens of pharmacies around Austin, Texas, trying to fill a prescription for ...

A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...

Last year, President Donald Trump told pregnant women not to take Tylenol as he promoted unproven ties between the fever reducer and autism and touted an old generic drug as a treatment for the ...

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Prior authorization requires doctors to get approval from a patient’s insurance company before they’ll cover a procedure, prescription or a service such as an imaging exam. Companies use the process ...

Women and girls bear the brunt of collapsing healthcare and mass displacement Medical staff describe an exponential rise in maternal and neo-natal health ...

Many cancer treatments were developed for adult physiology, not pediatric biology, resulting in disproportionate long-term ...

When someone is diagnosed with chronic leukaemia, the first focus is often the cancer itself. What stage is it? How active is it? What are the treatment options?But in real life, very few patients ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...